IRLAB Therapeutics (IRLAB) Q1 2026 earnings summary

Executive summary

• Achieved a $3M milestone in the LIFT-PD study for Parkinson's disease and apathy, with first patients dosed and ongoing enrollment, earning international recognition for investigational drugs.

• Strengthened financial position through a rights issue of SEK 68 million and an overallotment issue of SEK 34 million, with strong support from shareholders and management.

• Presented positive REACT-PD study results for pirepemat at an international conference, strengthening expert interest.

• Expanded board with pharma business expertise and continued to advance a broad portfolio of drug candidates.

• Focused on strategic partnerships, cost efficiency, and advancing key pipeline projects.

Financial highlights

• Net sales increased to SEK 39.4m in Q1 2026 from SEK 4.4m in Q1 2025, mainly from milestone payments.

• Operating profit reached SEK 10.7m, reversing a loss of SEK -28.6m year-over-year.

• Earnings per share improved to SEK 0.11 from SEK -0.65 year-over-year.

• Cash and cash equivalents decreased to SEK 50.8m from SEK 88.6m year-over-year.

• Cash flow from operating activities was SEK -28.7m, down from SEK 12.3m in Q1 2025.

Outlook and guidance

• Fully funded through Q4 2027 if rights issue and loan extension are completed.

• Focus on securing at least one revenue-generating collaboration agreement during the year.

• IRL757 expected to reach data readout in mid-2027; decision on next steps for pirepemat due by Q2 2026.

• Continued advancement of IRL1117 towards Phase I and ongoing development of other pipeline candidates.

• Strategic priorities include deepening partnerships, securing funding, and progressing clinical studies for key assets.